Sign up for the Race/Related Newsletter join a deep and provocative exploration of race identity and society with New York Times journalists. Get it sent to your inbox.
Lupin announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release
Tablets, 4 mg and 8 mg, to market a generic equivalent of Toviaz Extended-Release Tablets, 4 mg and 8 mg, of Pfizer Inc.
The product will be manufactured at Lupin's facility in Goa, India.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
